<DOC>
	<DOCNO>NCT00004036</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor divide stop grow die . Chemoprotective drug , amifostine , may protect normal cell side effect chemotherapy . PURPOSE : Phase I trial study effectiveness amifostine plus combination chemotherapy treat patient advanced cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Amifostine Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect prim granulocyte thrombocyte nadir produce high dose cyclophosphamide carboplatin patient advanced malignancy . II . Determine effect amifostine granulocyte thrombocyte nadir produce regimen administer sargramostim prim progenitor cell . III . Determine maximum tolerate dose cyclophosphamide carboplatin administer sargramostim prim progenitor cell . OUTLINE : This dose escalation study . Patients receive intravenous amifostine 10 minute day 0 , follow intravenous cyclophosphamide carboplatin consecutively 5-15 minute . Sargramostim administer subcutaneously day -7 -2 begin day 1 absolute neutrophil count appropriate . Course repeat every 28 day disease progression unacceptable toxic effect observe . Nonresponding patient discontinue treatment 2 course . Patients treat maximum 6 course . Groups 3-6 patient receive escalate dos cyclophosphamide carboplatin maximum tolerate dose ( MTD ) determine . If dose limit toxicity ( DLT ) occur 2 6 patient give dose level , dose escalation cease next low dose declare MTD . PROJECTED ACCRUAL : Approximately 24-30 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced malignancy sensitive cyclophosphamide/carboplatin therapy OR refractory standard therapy , include , limited : Ovarian epithelial cancer Colorectal cancer Breast cancer Sarcoma Nonsmall cell lung cancer Malignant melanoma Upper gastrointestinal cancer Small cell lung cancer PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 SWOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8.5 g/dL Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min OR Iothalamate clearance least 60 mL/min Cardiovascular : No significant coronary artery disease ( angina New York Heart Association class 3 great ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychosis PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 3 week since prior chemotherapy recover No 1 prior chemotherapy regimen advance recurrent malignancy ( include adjuvant chemotherapy ) No prior nitrosoureas intravenous mitomycin No concurrent cytotoxic chemotherapy Endocrine therapy : At least 1 week since prior hormone therapy recover Concurrent corticosteroid therapy allow Radiotherapy : At least 3 week since prior radiotherapy recover Radiotherapy allow 1 site thoracic lumbar spine pelvis Concurrent radiotherapy symptomatic lesion allow first course study treatment Surgery : At least 3 week since prior surgery recover ( exclude recent biopsy placement intravenous access device )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>